US 12,447,213 B2
Modulation of novel immune checkpoint targets
Vijay K. Kuchroo, Newton, MA (US); Ana Carrizosa Anderson, Brookline, MA (US); Asaf Madi, Boston, MA (US); Norio Chihara, Boston, MA (US); Aviv Regev, Cambridge, MA (US); Meromit Singer, Cambridge, MA (US); and Huiyuan Zhang, Boston, MA (US)
Assigned to THE BROAD INSTITUTE, INC., Cambridge, MA (US); MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, MA (US); and THE BRIGHAM AND WOMEN'S HOSPITAL, INC., Boston, MA (US)
Appl. No. 16/340,376
Filed by The Brigham and Women's Hospital, Inc., Boston, MA (US); The Broad Institute, Inc., Cambridge, MA (US); and Massachusetts Institute of Technology, Cambridge, MA (US)
PCT Filed Oct. 6, 2017, PCT No. PCT/US2017/055625
§ 371(c)(1), (2) Date Apr. 8, 2019,
PCT Pub. No. WO2018/067991, PCT Pub. Date Apr. 12, 2018.
Claims priority of provisional application 62/405,835, filed on Oct. 7, 2016.
Prior Publication US 2020/0016202 A1, Jan. 16, 2020
Int. Cl. A61K 47/68 (2017.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 45/06 (2006.01); C07K 14/725 (2006.01); G01N 33/563 (2006.01); G01N 33/574 (2006.01)
CPC A61K 47/68 (2017.08) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4244 (2025.01); C07K 14/7051 (2013.01); G01N 33/563 (2013.01); G01N 33/574 (2013.01); A61K 45/06 (2013.01); A61K 2239/31 (2023.05); A61K 2239/57 (2023.05); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); G01N 2333/54 (2013.01); G01N 2333/70532 (2013.01)] 15 Claims
 
1. A method of modulating Th17 cells in a subject, comprising:
contacting a Th17 cell with one or more modulating agents that decreases activity, function, or a combination thereof of ILT-3;
wherein the one or more modulating agents comprises an antibody comprising (i) both variable regions of ZM3.8 or (ii) an antibody comprising both variable regions of ZM4.1, or a combination of (i) and (ii).